Immix Biopharma
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 17
- Market Cap
- $59.8M
- Website
- http://www.immixbio.com
- Introduction
Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis CAR-T Therapy Trial
Immix Biopharma successfully completed the six-patient Phase 1b safety run-in segment for NXC-201, a CAR-T therapy for relapsed/refractory AL Amyloidosis, accelerating U.S. enrollment. NXC-201, the only CAR-T therapy in development for AL Amyloidosis, showed no neurotoxicity and short cytokine release syndrome duration. Next update expected Q1 2025.
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T Therapy
Immix Biopharma successfully completed the six-patient Phase 1b safety run-in segment of the NEXICART-2 study for NXC-201, a CAR-T therapy for AL Amyloidosis, accelerating U.S. enrollment. NXC-201, the only one-time CAR-T therapy in development for this condition, showed no neurotoxicity and high complete response rates. Next update expected Q1 2025.
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
NXC-201, a CAR-T cell therapy by Immix Biopharma, showed a 75% complete response rate in relapsed/refractory AL Amyloidosis patients, with a favorable safety profile. The therapy is undergoing U.S. trials focusing on patients with preserved heart function, aiming to expand treatment options for this condition.
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR T NXC 201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024
Immix Biopharma reported a 75% complete response rate in relapsed/refractory AL Amyloidosis patients treated with NXC-201, with a best response duration of 31.5 months. The data, presented at ASH 2024, showed no neurotoxicity and a median CRS duration of 2 days. NXC-201 is under evaluation in Phase 1b/2 trials.
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T
Immix Biopharma successfully completed the six-patient Phase 1b safety run-in for NXC-201, a CAR-T therapy for AL Amyloidosis, accelerating U.S. enrollment. NXC-201, the only CAR-T therapy in development for this condition, showed no neurotoxicity and high complete response rates. Next update expected Q1 2025.
Stock Market News Today: SoundHound AI's Voice Commerce, Accenture's AI Report, OraSure's HIV Testing Expansion, Paychex's Acquisition, T2 Biosystems' Growth, Hasbro's MONOPOLY Update, Verizon's 5G Enhancement, Nokia's Lunar Network, Backblaze's Canada Expansion, Illumina's NovaSeq X Series Advancement
SoundHound AI unveiled a voice commerce platform for cars at CES 2025. Accenture's report highlights AI's role in business reinvention. OraSure expanded HIV self-testing to adolescents. Paychex acquired Paycor HCM for $4.1B. T2 Biosystems saw 37% revenue growth. Hasbro updated MONOPOLY for its 90th anniversary. Verizon enhanced 5G for the U.S. Air Force. Nokia completed a lunar cellular network. Backblaze expanded in Canada. Illumina advanced its NovaSeq X Series.
© Copyright 2025. All Rights Reserved by MedPath